SCA
COGT icon

Snowden Capital Advisors’s Cogent Biosciences COGT Stock Holding History

Snowden Capital Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,252
Closed -$202K – 1354
2026
Q1 		$202K Buy
+5,252
New +$194K 0.01% 1222

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Snowden Capital Advisors's COGT Position: Q2 2026 in Review

Snowden Capital Advisors sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 5,252 shares — an estimated $202K sold.

Snowden Capital Advisors first reported a position in COGT in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Snowden Capital Advisors reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Snowden Capital Advisors sold 5,252 Cogent Biosciences shares in Q2 2026, an estimated $202K.
  • Snowden Capital Advisors first reported a position in Cogent Biosciences in Q1 2026 and held it in 1 quarter.
  • Snowden Capital Advisors's Cogent Biosciences position peaked at $202K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.